This article has Open Peer Review reports available.
Reducing the environmental impact of trials: a comparison of the carbon footprint of the CRASH-1 and CRASH-2 clinical trials
© Subaiya et al; licensee BioMed Central Ltd. 2011
Received: 6 August 2010
Accepted: 3 February 2011
Published: 3 February 2011
All sectors of the economy, including the health research sector, must reduce their carbon emissions. The UK National Institute for Health Research has recently prepared guidelines on how to minimize the carbon footprint of research. We compare the carbon emissions from two international clinical trials in order to identify where emissions reductions can be made.
We conducted a carbon audit of two clinical trials (the CRASH-1 and CRASH-2 trials), quantifying the carbon dioxide emissions produced over a one-year audit period. Carbon emissions arising from the coordination centre, freight delivery, trial-related travel and commuting were calculated and compared.
The total emissions in carbon dioxide equivalents during the one-year audit period were 181.3 tonnes for CRASH-1 and 108.2 tonnes for CRASH-2. In total, CRASH-1 emitted 924.6 tonnes of carbon dioxide equivalents compared with 508.5 tonnes for CRASH-2. The CRASH-1 trial recruited 10,008 patients over 5.1 years, corresponding to 92 kg of carbon dioxide per randomized patient. The CRASH-2 trial recruited 20,211 patients over 4.7 years, corresponding to 25 kg of carbon dioxide per randomized patient. The largest contributor to emissions in CRASH-1 was freight delivery of trial materials (86.0 tonnes, 48% of total emissions), whereas the largest contributor in CRASH-2 was energy use by the trial coordination centre (54.6 tonnes, 30% of total emissions).
Faster patient recruitment in the CRASH-2 trial largely accounted for its greatly increased carbon efficiency in terms of emissions per randomized patient. Lighter trial materials and web-based data entry also contributed to the overall lower carbon emissions in CRASH-2 as compared to CRASH-1.
NIHR Guidelines for Carbon Reduction in Clinical Trials1
Setting the research question and full use of existing evidence
• Always carry out systematic reviews of existing evidence before new grant submission.
• Involve clinicians and patients in shaping applied research agendas.
Efficient study design
• Efficient use of resources such as patient populations and patient time.
• Consider the possibility of answering several questions through one study.
• Involve methodologists in research design.
Study set up
• Maximize professional assistance through research funders, clinical trial units, and NIHR networks to minimize time spent on bureaucratic process.
• Decrease time spent on patient recruitment.
Avoid unnecessary data collection
• Clear study protocols.
• Measure outcomes remotely when possible (phone, internet).
• If patient contact is necessary, utilize outcome assessors that are in close proximity to patients.
• Do not measure all outcomes on all patients if unnecessary.
Sensible clinical trial monitoring
• Focus on issues that are critical for safety and wellbeing of study participants and reliability of results.
• Avoid monitoring that requires extensive travel to study sites; limit travel to sites only when there is an issue or concern.
• Use centralized, systematic programs to ensure data authenticity and quality.
Good practice in research reporting
• Report results of new primary research within updated systematic reviews of other relevant research.
• Ensure research reports are presented in a manner that allows information to be utilized by readers.
The CRASH-1 and CRASH-2 trials were international multi centre randomized controlled trials conducted by the London School of Hygiene & Tropical Medicine (LSHTM). The CRASH-1 trial (April 1999- May 2004) evaluated the effect of corticosteroid administration on patient outcomes after traumatic brain injury. The CRASH-2 trial (May 2005- February 2010) examined the effect of tranexamic acid administration in bleeding trauma patients. The two trials were of similar design but greater effort was made to reduce the carbon footprint of the CRASH-2 trial using several of the strategies outlined in the NIHR carbon reduction guidelines. In this study we compared the greenhouse gas emissions of the CRASH-1 and CRASH-2 clinical trials.
Trial activities included in the carbon audit
• Natural Gas
• Heating Oil
Trial Related Travel
Trial Team Commuting
• Air freight
• Diesel Van
Sample calculation of trial related travel due to short-haul flights in the CRASH-1 trial
Total short-haul distance
Emissions for short-haul flights
3.3 × 10-5 +
1.3 × 105
Total = 3.3
The carbon emissions due to energy consumption (electricity, natural gas, heating oil and steam) and water by the coordinating centre premises could not be calculated directly. This was because of the open plan form of the trial offices and the fact that other non-trial activities were carried out in the same area during the conduct of both trials. Emissions were therefore estimated on the basis of average per person emissions from office space and the number of trial employees (9 in CRASH-1 and 7 in CRASH-2). Electricity consumption of the trial team was based upon percentage of total electricity consumed by the trial office.
Carbon dioxide equivalents are reported separately for CRASH-1 and CRASH-2 by source of emissions, including emissions from coordination centre, trial related travel, commuting and drug box shipments. Emissions per patient were calculated by dividing each trial's total greenhouse gas emissions estimated from the audit year by the total number of patients randomized.
Summary of Greenhouse Gas emissions by trial activity for the CRASH-1 and CRASH-2 trials
Source of Emissions
(tonnes of C02 equivalents/yr)
(tonnes of C02 equivalents/yr)
in emissions (%)
Coordination centre total
Trial related travel total
Trial team commuting total
Freight deliveries- Diesel vans
Freight deliveries- Air freight
Freight delivery total
Total Trial Emissions
Freight delivery of trial drugs
Freight delivery was the largest source of emissions for the CRASH-1 trial (86.0 tonnes, 48% of total emissions). It was the second largest source of emissions for the CRASH-2 trial (34.2 tonnes, 32% of total emissions). Air-transportation of treatment packs comprised the majority of freight emissions in both trials contributing 81.0 tonnes in CRASH-1 (94% of freight delivery emissions) and 29.0 tonnes in CRASH-2 (85% of freight delivery emissions). Emissions due to freight delivery emissions were 60% less in CRASH-2 as compared to CRASH-1.
The coordination centre was the second largest source of emissions for the CRASH-1 trial (54.6 tonnes, 30% of total emissions). It was the largest source of emissions for the CRASH-2 trial (39.5 tonnes, 37% of total emissions). Electricity use comprised the greatest proportion of emissions of the coordination centre and contributed 29.0 tonnes during CRASH-1 (53% of coordination centre emissions) and 23.0 tonnes during CRASH-2 (58% of coordination centre emissions). In both trials, the second largest proportion of emissions in this category was due to natural gas consumption. Overall, there was 28% less carbon emitted due to the coordination centre from CRASH-1 to CRASH-2.
Trial related travel
Trial related travel accounted for 37.3 tonnes (21% of total emissions) in CRASH-1 and 31.1 tonnes (29% of total emissions) in CRASH-2. Twenty-eight tonnes (75% of travel emissions) were due to air-travel in CRASH-1, and 29.0 tonnes (93% of travel emissions) were due to air-travel in CRASH-2. The remainder of carbon emissions in both trials was due to hotel stays. There was 17% less carbon emitted from CRASH-1 to CRASH-2 due to trial related travel.
Trial team commuting
Commuting accounted for 3.3 tonnes of emissions in both CRASH-1 and CRASH-2. The majority of emissions in both trials were due to underground tube travel, contributing 1.4 tonnes (42% of commuting emissions) in CRASH-1 and 2.0 tonnes (61% of commuting emissions) in CRASH-2.
The results of this comparative carbon audit show that the CRASH-2 trial was considerably more carbon efficient than CRASH-1, both in regards to the amount of carbon emitted per randomized patient and in terms of total emissions. The main reason was that the CRASH-2 trial recruited more than twice as many patients in a shorter time frame than CRASH-1. This in turn was facilitated by the strong clinician interest in the research question, the use of an established network of international collaborators and the use of a simple trial design with data collection limited to key clinically relevant end points. The more efficient recruitment in the CRASH-2 trial helped to minimize carbon emissions per randomized patient.
Differences in the emissions arising from the delivery of trial drugs accounted for a large part of the difference in total carbon emissions between the trials. The trial treatment in CRASH-2 was lighter and more compact than in CRASH-1, weighing approximately 2.5 kg and 9 kg respectively. Each treatment pack in the CRASH-1 trial contained 11 glass vials approximately 5 cm in height and width that had to be protected from breakage during transit by means of protective packaging. On the other hand, the CRASH-2 treatment pack contained four small ampoules that required less protection. Despite a larger number of delivery sites in CRASH-2, emissions were nevertheless reduced in this sector illustrating how logistics can have an important impact on carbon emissions.
Emissions from the coordination centre were slightly lower for CRASH-2 than for CRASH-1. The carbon emissions from the coordinating centre were based on the number of office staff and there were fewer staff in CRASH-2 than in CRASH-1. In the CRASH-1 trial, handwritten data received by fax were double entered by two staff members at the coordination centre. CRASH-2 used direct data entry, which reduced the need for data entry staff as well as reducing the risk of transcription errors.
Trial-related travel often comprises an important source of emissions in clinical trials and limiting unnecessary travel can reduce their carbon footprint . Greater use of statistical data checking algorithms has been suggested as a strategy to reduce the need for on-site data monitoring and these methods were employed in both trials . Additionally, teleconferencing, video-conferencing and web based training materials can be used to reduce travel.
Strengths and limitations
This study collected information on all sources of carbon emissions for two large multi centre trials. The same methodology was used to determine carbon emissions for CRASH-1 and CRASH-2, helping to ensure a valid comparison between trials. Furthermore, the audit was carried out by an independent, third party organization with extensive experience in quantifying and verifying GHG emissions from operational activities.
However, our study has limitations. The audit period was for only one year and extrapolation to the entire trial may have led to inaccuracy. Data were collected retrospectively, whereas prospective data collection would have been more accurate. The energy consumption of the coordination centre was not obtained by direct measurement, which could lead to errors in estimation of the true carbon emissions. Although the most up-to-date standardized carbon conversion factors were used, the science behind these equivalents is still developing and estimates may not represent actual carbon dioxide equivalent emissions. However, since the same conversion factors were applied to both trials, the comparison between trials and demonstrated reduction is internally valid.
This study has shown that the efficiency of patient recruitment is a major determinant of the environmental impact of a clinical trial. There is a limit to the amount of greenhouse gases that can be emitted without causing serious climate destabilization. If society decides to allocate a proportion of its limited carbon budget to obtaining information on the safety and effectiveness of a health care intervention, then both researchers and research regulators have the responsibilities to ensure that the research is conducted as efficiently as is consistent with patient safety and that it provides valid and reliable information.
In the UK, there is a growing consensus that the regulation and governance framework for clinical trials has become an obstacle to their efficient conduct . The Academy of Medical Sciences has been commissioned by the UK Government to undertake an independent review of the regulation and governance of medical research . Although the CRASH-2 trial recruited patients more rapidly than its predecessor, this was largely driven by recruitment in Asia, South America and Africa, while recruitment in the UK was much less than anticipated largely due to these regulatory changes implemented after CRASH-1 . Streamlining and improving the regulatory environment has the potential to increase both the carbon and cost effectiveness of medical research.
Although efforts to reduce the carbon footprint of clinical trials are essential, it is important to acknowledge that healthcare itself is a major source of carbon emissions and that by ensuring the provision of safe and effective healthcare, health research plays a central role in avoiding medical waste. Pharmaceutical use is particularly carbon intensive and makes a major contribution to the carbon footprint of the NHS. The CRASH-1 trial showed that a drug that had been used in the treatment of head injury patients for over thirty years was at best ineffective, and probably harmful . The carbon cost of obtaining reliable information from well-conducted clinical studies is likely to be dwarfed by that of using treatments that are ineffective or harmful.
In summary, a number of strategies can be used to reduce the carbon footprint of clinical research. Although it is not always possible to reduce the weight and shipping distance of trial materials, the use of lightweight packaging can have an important impact on emissions. Statistical data monitoring, web-based training materials and tele-conferencing can help reduce travel. Direct data entry can reduce the need for transcription and will also lessen emissions from trial office space. While the focus of this study was on emissions from non-commercial clinical trials, the extent to which the principles might be applied in pharmaceutical industry directed trials is open to question. Industry led trials are often considerably more complex and involve much more data collection than non-commercial trials. On the other hand, it is likely that the carbon footprint of industry led trials is much larger, and the need to make emissions reductions even more important.
We thank the Edinburgh Centre for Carbon Management, Maria Ramos, Lin Barnetson and Sheila Scott for their help with the data collection and analyses.
- Department for Food and Rural Affairs: Climate Change Act 2008. DEFRA. 2008, London, United KingdomGoogle Scholar
- World Medical Association: World Medical Association Declaration of Helsinki. WMA General Assembly. 1964, Helsinki, Finland.http://ohsr.od.nih.gov/guidelines/helsinki.html Google Scholar
- World Business Council for Sustainable Development: Calculations Tools. 2005.http://www.ghgprotocol.org/ Google Scholar
- Department for Food and Rural Affairs: 2009 Guidelines to Defra/DECC's GHG Conversion Factors for Company Reporting. DEFRA. 2009.http://www.defra.gov.uk/environment/business/reporting/pdf/20090928-guidelines-ghg-conversion-factors.pdf Google Scholar
- Intergovernmental Panel on Climate Change: IPCC Guidelines for National Greenhouse Gas Inventories: Reference Manual. IPCC. 2006.http://www.ipcc-nggip.iges.or.jp/public/2006gl/pdf/0_Overview/V0_0_Cover.pdf Google Scholar
- SCLCI 2009: Swiss Centre for Lifecycle Inventories 2009. SCLCI. 2009Google Scholar
- Business Enterprise and Regulatory Reform: Digest of UK energy statistics. BERR. 2008Google Scholar
- Boeing: Range and fuel capacity data. 2007.http://www.boeing.com/commercial/737family/pf/pf_700tech.html Google Scholar
- Carbon Trust: Energy and carbon conversions. 2006Google Scholar
- Webflyer: Mileage Calculator. 2010.http://www.webflyer.com/travel/mileage_calculator/ Google Scholar
- World Airport Codes. 2010.http://www.world-airport-codes.com/
- Lyle K, Dent L, Bailey S, Kerridge L, Roberts I, Milne R: Carbon cost of pragmatic randomized controlled trials: retrospective analysis of sample of trials. BMJ. 2009, 339: b4187-10.1136/bmj.b4187.View ArticlePubMedPubMed CentralGoogle Scholar
- Al-Marzouki S, Evans S, Marshall T, Roberts I: Are these data real? Statistical methods for the detection of data fabrication in clinical trials. BMJ. 2005, 331 (7511): 267-70. 10.1136/bmj.331.7511.267.View ArticlePubMedPubMed CentralGoogle Scholar
- McMahon A, Conway D, MacDonald T, McInnes G: The unintended consequences of clinical trials regulations. PLoS Med. 2009, 6 (22): e1000131-10.1371/journal.pmed.1000131.View ArticlePubMed CentralGoogle Scholar
- The Academy of Medical Sciences: Review of the regulation and governance of medical research. AMS. 2010.http://www.acmedsci.ac.uk/download.php?file=/images/project/AMSRGrev.pdf Google Scholar
- Wilkinson E: EU red tape 'blocks drug trials". BBC News Health. 2009, London, United Kingdom.http://news.bbc.co.uk/1/hi/health/7939606.stm Google Scholar
- The CRASH Trial Collaborators: Effect of intravenous corticosteroids on death within 14 days in 10,008 adults with clinically significant head injury (MRC CRASH Trial): a randomised placebo-controlled trial. Lancet. 2004, 364: 1321-28. 10.1016/S0140-6736(04)17188-2.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.